Clinical trial demonstrates humoral immunogenicity and acceptable safety of mRNA-1345 vaccine in adults aged ≥60 years, highlighting protection against respiratory syncytial virus.
The mRNA-1345 vaccine demonstrated efficacy against respiratory syncytial virus (RSV) disease with acceptable safety in adults aged ≥60 years in the ConquerRSV trial. Here, humoral immunogenicity results from the trial are presented.
No takes yet. Share an insight, caveat, or question.
Goswami et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: